From engineered decoy proteins to neutralizing antibodies, discover some of the latest therapeutic agents against SARS-CoV-2 and its variants.

Register for the Webinar

Already registered?
Access the webinar here »

It has been two and a half years since the emergence of the SARS-CoV-2 virus and the COVID-19 outbreak. Despite the success of safe and efficacious vaccines for COVID-19, people still fall ill due to viral infection and the ensuing complications. With the continual emergence of SARS-CoV-2 variants of interest, the threat is far from over. In this webinar, Lianghui (Lucy) Zhang and Michael Cobas Meyer will discuss strategies employed by scientists to develop effective therapies for COVID-19.

Topics to be covered

  • Targeting SARS-CoV-2 variants with an engineered protein decoy
  • Using the monoclonal antibody, bebtelovimab against SARS-CoV-2 and variants of concern


Lianghui (Lucy) Zhang, MD, PhD

Lianghui (Lucy) Zhang, MD, PhD
Assistant Professor
Department of Pharmacology & Regeneration
University of Illinois at Chicago

Michael Cobas Meyer, MD

Michael Cobas Meyer, MD
Vice President
Neuroscience Pain Early and Late Phase Development and Lilly Research Laboratories COVID-19 Therapies
Eli Lilly and Company

Webinar Sponsors


Sino Biological Logo

ATCC logo

Molecular Devices_Logo_Color